98%
921
2 minutes
20
Objective: To evaluate multiple determinants of the longitudinal change in insulin clearance (IC) in subjects at high risk for type 2 diabetes (T2D).
Research Design And Methods: Adults (n=492) at risk for T2D in the Prospective Metabolism and Islet Cell Evaluation cohort, a longitudinal observational cohort, had four visits over 9 years. Values from oral glucose tolerance tests collected at each assessment were used to calculate the ratios of both fasting C peptide-to-insulin (IC) and areas under the curve of C peptide-to-insulin (IC). Generalized estimating equations (GEE) evaluated multiple determinants of longitudinal changes in IC.
Results: IC declined by 20% over the 9-year follow-up period (p<0.05). Primary GEE results indicated that non-European ethnicity, as well as increases in baseline measures of waist circumference, white cell count, and alanine aminotransferase, was associated with declines in IC and IC over time (all p<0.05). There were no significant associations of IC with sex, age, physical activity, smoking, or family history of T2D. Both baseline and longitudinal IC were associated with incident dysglycemia.
Conclusions: Our findings suggest that non-European ethnicity and components of the metabolic syndrome, including central obesity, non-alcoholic fatty liver disease, and subclinical inflammation, may be related to longitudinal declines in IC.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6887510 | PMC |
http://dx.doi.org/10.1136/bmjdrc-2019-000825 | DOI Listing |
Periodontol 2000
September 2025
Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Oral cancer is a major global health burden, ranking sixth in prevalence, with oral squamous cell carcinoma (OSCC) being the most common type. Importantly, OSCC is often diagnosed at late stages, underscoring the need for innovative methods for early detection. The oral microbiome, an active microbial community within the oral cavity, holds promise as a biomarker for the prediction and progression of cancer.
View Article and Find Full Text PDFEur J Neurol
September 2025
Pain Treatment and Evaluation Center, CHU Timone, Assistance Publique des Hôpitaux de Marseille, Marseille, France.
Background: Neuropathic pain (NP) is frequently resistant to conventional treatments. Botulinum toxin type A (BT-A) is a recommended option for focal peripheral NP, but the dynamics of its effect in real-life conditions remain poorly characterized.
Objective: To assess BT-A efficacy in a real-world study of patients with focal peripheral NP, over a 1-year follow-up period.
J Cachexia Sarcopenia Muscle
October 2025
Department of Surgery, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, the Netherlands.
Background: Body composition alterations such as skeletal muscle (SM) loss in cancer patients are associated with poor survival. In turn, immune cell-driven pathways have been linked to muscle wasting. We aimed to investigate the relationship between body composition, tumour-infiltrating lymphocytes and survival in patients with advanced lung cancer.
View Article and Find Full Text PDFJ Orthop Res
September 2025
Interdisciplinary Orthopedics, Department of Orthopedics Surgery, Aalborg University Hospital, Aalborg, Denmark.
Functional recovery after total knee arthroplasty (TKA) varies widely among individuals, and traditional assessments often fail to detect subtle changes in real-world walking ability. Wearable sensors offer continuous and objective tracking of gait outside of clinical settings. In this prospective, longitudinal study, thirty-one patients undergoing unilateral TKA wore thigh-mounted accelerometers continuously from 2 weeks before surgery through 90 days postoperatively.
View Article and Find Full Text PDF